Sun Pharma's ILUMYA approved in US for Psoriatic Arthritis

Sun Pharmaceutical Industries Limited announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for ILUMYA® (tildrakizumab-asmn). This approval expands the use of ILUMYA beyond moderate-to-severe plaque psoriasis to include the treatment of adults with active psoriatic arthritis (PsA). The approval is based on positive results from the Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies. ILUMYA is an IL-23 inhibitor administered by healthcare providers, offering a new treatment option for approximately 2.4 million Americans living with psoriatic arthritis. This marks a significant milestone for Sun Pharma, strengthening its portfolio in psoriatic disease management.